{"title":"Incidence and Clinical Utilization of Radiotherapy of Childhood Tumors in South Korea Using National Health Insurance Sharing Service Data","authors":"J. Chung , H. Lim , J. Kim","doi":"10.1016/j.ijrobp.2024.11.044","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>This study aimed to evaluate the clinical utilization of radiotherapy for childhood tumors in South Korea using National Health Insurance Sharing Service (NHISS) data.</div></div><div><h3>Methods</h3><div>Children aged 19 or younger diagnosed with childhood tumors from 2003 to 2020 were identified in the NHISS data using the International Classification of Disease 10 (ICD-10) codes C and D. Data from 2003 and 2004 were excluded to adjust for the washout period.</div></div><div><h3>Results</h3><div>Between 2005 and 2020, 36,152 patients were diagnosed with childhood tumors. The distribution over four-year intervals was as follows: 13,716 (0.11% of total population) in the first quadrennial period (2005-2008), 8,846 (0.08%) in the second (2009-2012), 6,893 (0.07%) in the third (2013-2016), and 6,697 (0.07%) in the fourth (2017-2020). Regarding radiotherapy, of the total patients aged 19 or younger, 5.6% underwent treatment in the first period, 10.0% in the second, 11.7% in the third, and 11.7% in the fourth. Among those treated with radiotherapy, 2-dimensional (2D), 3D-conformal radiotherapy (3D-CRT), intensity-modulated radiotherapy (IMRT) and proton therapy were used in 110 (14.3%), 608 (79.1%), 34 (4.4%) and 8 (1.0%) cases in the first quadrennial period, 50 (5.7%), 604 (68.3%), 170 (19.2%) and 53 (6.0%) cases in the second, 18 (2.2%), 310 (38.4%), 364 (45.0%) and 116 (14.4%) cases in the third, and 4 (0.6%), 83 (12.7%), 405 (61.8%) and 162 (24.7%) cases in the fourth, respectively. The most common tumors treated with radiotherapy, in order of prevalence, were brain (C71; e.g., ependymoma, n=986), benign neoplasm of central nervous system (D33, D43; e.g., craniopharyngioma, n=764), primary bone and cartilage (C40-41; e.g., osteosarcoma, n=286), non-Hodgkin's lymphoma (C83.7 and C85; e.g., b-cell lymphoma, n=200), soft tissue (C46 and C49.9; e.g., rhabdomyosarcoma, n=186), endocrine (C74-75; e.g., adrenal gland tumor, n=164), Hodgkin lymphoma (C81, n=123), and nasopharyngeal cancer (C11.9, n=92).</div></div><div><h3>Conclusions</h3><div>Despite the declining birth rate, the overall incidence rate of childhood tumors remains steady at approximately 0.07% of the total population. Radiotherapy utilization rate showed an increasing trend according to the more recent quadrennial period. This trend may be associated with the introduction of more advanced radiotherapy techniques with extended national health insurance coverage. This tendency was repeatedly manifested in the subset of patients with CNS tumors.</div></div>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"121 3","pages":"Page e12"},"PeriodicalIF":6.4000,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0360301624036186","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives
This study aimed to evaluate the clinical utilization of radiotherapy for childhood tumors in South Korea using National Health Insurance Sharing Service (NHISS) data.
Methods
Children aged 19 or younger diagnosed with childhood tumors from 2003 to 2020 were identified in the NHISS data using the International Classification of Disease 10 (ICD-10) codes C and D. Data from 2003 and 2004 were excluded to adjust for the washout period.
Results
Between 2005 and 2020, 36,152 patients were diagnosed with childhood tumors. The distribution over four-year intervals was as follows: 13,716 (0.11% of total population) in the first quadrennial period (2005-2008), 8,846 (0.08%) in the second (2009-2012), 6,893 (0.07%) in the third (2013-2016), and 6,697 (0.07%) in the fourth (2017-2020). Regarding radiotherapy, of the total patients aged 19 or younger, 5.6% underwent treatment in the first period, 10.0% in the second, 11.7% in the third, and 11.7% in the fourth. Among those treated with radiotherapy, 2-dimensional (2D), 3D-conformal radiotherapy (3D-CRT), intensity-modulated radiotherapy (IMRT) and proton therapy were used in 110 (14.3%), 608 (79.1%), 34 (4.4%) and 8 (1.0%) cases in the first quadrennial period, 50 (5.7%), 604 (68.3%), 170 (19.2%) and 53 (6.0%) cases in the second, 18 (2.2%), 310 (38.4%), 364 (45.0%) and 116 (14.4%) cases in the third, and 4 (0.6%), 83 (12.7%), 405 (61.8%) and 162 (24.7%) cases in the fourth, respectively. The most common tumors treated with radiotherapy, in order of prevalence, were brain (C71; e.g., ependymoma, n=986), benign neoplasm of central nervous system (D33, D43; e.g., craniopharyngioma, n=764), primary bone and cartilage (C40-41; e.g., osteosarcoma, n=286), non-Hodgkin's lymphoma (C83.7 and C85; e.g., b-cell lymphoma, n=200), soft tissue (C46 and C49.9; e.g., rhabdomyosarcoma, n=186), endocrine (C74-75; e.g., adrenal gland tumor, n=164), Hodgkin lymphoma (C81, n=123), and nasopharyngeal cancer (C11.9, n=92).
Conclusions
Despite the declining birth rate, the overall incidence rate of childhood tumors remains steady at approximately 0.07% of the total population. Radiotherapy utilization rate showed an increasing trend according to the more recent quadrennial period. This trend may be associated with the introduction of more advanced radiotherapy techniques with extended national health insurance coverage. This tendency was repeatedly manifested in the subset of patients with CNS tumors.
期刊介绍:
International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field.
This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.